Prognosis of Primary Liver Cancer Based on LI-RADS Classification with Extracellular Agent-Enhanced MRI

References

• Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787–1794. doi:10.1200/JCO.2015.64.7412
   PubMed Web of Science ®Google Scholar
• Kierans AS, Makkar J, Guniganti P, et al. Validation of liver imaging reporting and data system 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging. 2019;49(7):e205–e15.
   PubMed Web of Science ®Google Scholar
• van der Pol CB, Lim CS, Sirlin CB, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-A systematic review. Gastroenterology. 2019;156(4):976–986.
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee SS, Kim SY, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology. 2017;282(3):771–781.
   PubMed Web of Science ®Google Scholar
• Kim HD, Lim YS, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology. 2015;148(7):1371–1382.
   PubMed Web of Science ®Google Scholar
• Garancini M, Goffredo P, Pagni F, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl. 2014;20(8):952–959.
   PubMed Web of Science ®Google Scholar
• Jiang H, Song B, Qin Y, et al. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol. 2021;31(6):3638–3648.
   PubMed Web of Science ®Google Scholar
• Elsayes KM, Hooker JC, Agrons MM, et al. 2017 Version of LI-RADS for CT and MR Imaging: an Update. RadioGraphics. 2017;37(7):1994–2017.
   PubMed Web of Science ®Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816–830.
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee SS, Park SH, et al. LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology. 2019;290(2):388–397.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol. 2020;26(3):340–351.
   PubMed Web of Science ®Google Scholar
• Hope TA, Fowler KJ, Sirlin CB, et al. Hepatobiliary agents and their role in LI-RADS. Abdom Imaging. 2015;40(3):613–625.
   PubMedGoogle Scholar
• Chanyaputhipong J, Low SC, Chow PK. Gadoxetate acid-enhanced MR Imaging for HCC: a review for clinicians. Int J Hepatol. 2011;2011:489342.
   PubMedGoogle Scholar
• Tamada T, Ito K, Sone T, et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging. 2009;29(3):636–640.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200(1):59–67.
   PubMed Web of Science ®Google Scholar
• Min JH, Kim JM, Kim YK, et al. Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the liver imaging reporting and data system. Hepatology. 2018;68(6):2254–2266.
   PubMed Web of Science ®Google Scholar
• Davenport MS, Viglianti B, Al-Hawary MM, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266(2):452–461.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu G-Q, Zhou C-W, Li N, Yang C, Zeng M-S. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors. European Radiology. 2022;32(8):5166–5178.
   PubMed Web of Science ®Google Scholar
• Hwang J, Kim YK, Min JH, et al. Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (>/=5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI. Eur Radiol. 2017;27(11):4581–4590.
   PubMed Web of Science ®Google Scholar
• Choi SY, Kim YK, Min JH, et al. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2018;28(6):2549–2560.
   PubMed Web of Science ®Google Scholar
• Huang P, Zhou C, Wu F, et al. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI. European Radiology. 2020;2020:1432. doi:10.1007/s00330-022-09282-5
   Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:1365–2559.
   Web of Science ®Google Scholar
• Kim -Y-Y, Kim M-J, Kim EH, Roh YH, An C. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: performance of LI-RADS version 2018. Radiology. 2019;291(1):72–80.
   PubMed Web of Science ®Google Scholar
• Fraum TJ, Tsai R, Rohe E, et al. Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology. 2018;286(1):158–172.
   PubMed Web of Science ®Google Scholar
• Kim YY, An C, Kim S, Kim MJ. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. 2018;28(5):2038–2046.
   PubMed Web of Science ®Google Scholar
• Choi SY, Kim SH, Park CK, et al. Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study. Radiology. 2018;286(3):897–908.
   PubMed Web of Science ®Google Scholar
• Joseph NM, Tsokos CG, Umetsu SE, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019;248(2):164–178.
   PubMed Web of Science ®Google Scholar
• Xue R, Chen L, Zhang C, et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell. 2019;35(6):932–47 e8.
   PubMed Web of Science ®Google Scholar
• Yoon J, Hwang JA, Lee S, Lee JE, Ha SY, Park YN. Clinicopathologic and MRI features of combined hepatocellular-cholangiocarcinoma in patients with or without cirrhosis. Liver Int. 2021;41(7):1641–1651.
   PubMed Web of Science ®Google Scholar
• Tang Y, Wang L, Teng F, Zhang T, Zhao Y, Chen Z. The clinical characteristics and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma after surgical resection: a propensity score matching analysis. Int J Med Sci. 2021;18(1):187–198.
   PubMed Web of Science ®Google Scholar
• Ishii T, Ito T, Sumiyoshi S, et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World J Surg Oncol. 2020;18(1):319.
   PubMed Web of Science ®Google Scholar
• Chu KJ, Lu CD, Dong H, Fu XH, Zhang HW, Yao XP. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Eur J Gastroenterol Hepatol. 2014;26(2):192–199.
   PubMed Web of Science ®Google Scholar
• Zhou YM, Sui CJ, Zhang XF, Li B, Yang JM. Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma. BMC Gastroenterol. 2017;17(1):25.
   PubMedGoogle Scholar
• Ludwig DR, Fraum TJ, Cannella R, et al. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of liver imaging reporting and data system v2018. Abdom Radiol. 2019;44(6):2116–2132.
   PubMed Web of Science ®Google Scholar
• Fraum TJ, Cannella R, Ludwig DR, et al. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors. Eur Radiol. 2020;30(2):996–1007.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang W, Ma X, et al. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Eur Radiol. 2020;30(10):5337–5347.
   PubMed Web of Science ®Google Scholar
• Lu XY, Xi T, Lau WY, et al. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol. 2011;137(4):567–575.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wang Y, Ma L, Qian X, Yang C, Zeng M. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol. 2022;32(1):78–88.
   PubMed Web of Science ®Google Scholar